TRIPLE NEGATIVE BREAST CANCER

This study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This study tested a new drug called nadunolimab, which blocks a protein that helps cancer grow, combined with standard chemotherapy for people with advanced triple-negative breast cancer. The trial had two parts: first to find a safe dose, then to see if the combination shrinks t…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with metastatic or recurrent triple-negative breast cancer live longer without their cancer growing. The study included 531 participants and compared…

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This completed phase 2 trial tested a combination of sintilimab (an immunotherapy), anlotinib (a drug that blocks blood vessel growth), and standard chemotherapy in 29 people with early-stage triple-negative breast cancer. The treatment was given before surgery to shrink or elimi…

This study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researcher…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study tested a specific chemotherapy combination given before surgery for people with triple-negative breast cancer. The goal was to see if the treatment could completely eliminate the cancer from the breast and lymph nodes. 29 participants received the drugs, and the main o…

This study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had spread. Participants had not received prior chemotherapy for their advanced disease. The main goal…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested a new immune-boosting treatment called IRX-2 in 16 people with early stage breast cancer. The goal was to see if giving IRX-2 before chemotherapy is safe and helps the immune system fight the tumor. The treatment was given before surgery, and researchers looked …

This phase 2 trial tested whether adding loperamide (Imodium) and a white blood cell booster (G-CSF) could reduce severe diarrhea and low white blood cell counts caused by the drug Trodelvy in people with advanced breast cancer. Fifty patients with metastatic triple-negative or l…

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or o…

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…

This early study tested a combination of a modified herpes virus (T-VEC) and an immunotherapy drug (atezolizumab) in 28 women with aggressive breast cancer that did not fully disappear after standard chemotherapy. The virus was injected directly into tumors to kill cancer cells a…

This study tested a new radioactive tracer called 89Zr-TLX250 for PET scans in 12 people with metastatic triple negative breast cancer. The goal was to see if it could find more tumors than the standard FDG PET scan, especially in the brain. Researchers compared the number of les…

This study looked at whether women with early-stage breast cancer benefit from having a breast MRI in addition to standard mammograms before surgery. Researchers tracked 319 women to see if the MRI helped reduce the chance of cancer coming back, lowered the need for repeat surger…

This study tested three types of messages to encourage genetic testing in 1,283 people at risk for hereditary breast and ovarian cancer. Participants received an electronic health record message, then a text message, then a doctor's reminder if needed. The goal was to see which a…

This study looked at whether the types of bacteria in the gut and inside tumors affect how well chemotherapy works in triple negative breast cancer. Researchers followed 49 patients receiving standard chemotherapy before surgery. They collected samples to see if certain bacteria …

This study tested two chemotherapy drugs, cisplatin and paclitaxel, given before surgery to 147 women with triple negative breast cancer. The goal was to see if a genetic test called HRD could predict which drug would work better. Researchers measured how much the tumor shrank af…

This study aimed to create a communication tool to help doctors and patients discuss when cancer stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, parents of children with cancer, and heal…